Amylin narrows losses after reining in costs
This article was originally published in Scrip
Amylin Pharmaceuticals has edged closer towards being cash-flow positive after its non-GAAP operating net loss almost halved. The company reported a second-quarter net operating loss of $22 million following a rigorous cost-cutting programme. First-half non-GAAP net loss also fell by half to $42 million.